Clinical Trial Update: Aspirin to Target Arterial Events in Chronic Kidney Disease [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating aspirin to reduce arterial events in chronic kidney disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Chronic Kidney Disease

Drugs mentioned

• Aspirin (Aspirin)

Snippet

Sponsor: University of Southampton | Conditions: Chronic Kidney Diseases, Cardiovascular Diseases | Phase 3 | Status: TERMINATED